[ADVERT]
Share Name Share Symbol Market Type Share ISIN Share Description
Renalytix Plc LSE:RENX London Ordinary Share GB00BYWL4Y04 ORD 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  10.00 1.47% 690.00 680.00 700.00 690.00 690.00 690.00 0.00 08:00:01
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -10.6 -16.0 - 498

Renalytix PLC Exercise of Options and TVR

19/07/2021 3:02pm

UK Regulatory (RNS & others)


Renalytix (LSE:RENX)
Historical Stock Chart


From Jun 2021 to Sep 2021

Click Here for more Renalytix Charts.

TIDMRENX

RNS Number : 7167F

Renalytix PLC

19 July 2021

Renalytix plc

("Renalytix" or the "Company")

Exercise of Options and TVR

NEW YORK, 19 July, 2021 - Renalytix plc (AIM: RENX) announces that it has issued and allotted 5,000 ordinary shares of 0.25 pence each in the share capital of the Company ("Ordinary Shares") following an exercise of options on 19 July 2021. The exercise price was 585 pence per Ordinary Share.

Application has been made to the London Stock Exchange for the new Ordinary Shares to be admitted to trading on AIM. It is expected that admission of the 5,000 new Ordinary Shares to trading on AIM will become effective on, or around, 23 July 2021 ("Admission").

Total voting rights

Following Admission, the Company will have 72,229,786 Ordinary Shares in issue with each share carrying the right to one vote. The Company has no Ordinary Shares held in treasury. The total number of voting rights in the Company following Admission will therefore be 72,229,786.

For further information, please contact:

 
Renalytix plc                                                www.renalytix.com 
James McCullough, CEO                                          Via Walbrook PR 
 
Stifel (Nominated Adviser, Joint Broker)                    Tel: 020 7710 7600 
Alex Price / Nicholas Moore 
 
Investec Bank plc (Joint Broker)                            Tel: 020 7597 4000 
Gary Clarence / Daniel Adams 
 
Walbrook PR Limited             Tel: 020 7933 8780 or renalytix@walbrookpr.com 
Paul McManus / Lianne Cawthorne             Mob: 07980 541 893 / 07584 391 303 
 
 

About Kidney Disease

Kidney disease is now recognized as a public health epidemic affecting over 850 million people globally. The Centers for Disease Control and Prevention (CDC) estimates that 15% of US adults, or 37 million people, currently have chronic kidney disease (CKD). Further, the CDC reports that 9 out of 10 adults with CKD do not know they have it and one out of two people with very low kidney function who are not on dialysis do not know they have CKD.(1) Kidney disease is referred to as a "silent killer" because it often has no symptoms and can go undetected until a very advanced stage. Each year, kidney disease kills more people than breast and prostate cancer. Every day, 13 patients in the United States die while waiting for a kidney transplant.

   (1)   https://www.cdc.gov/kidneydisease/publications-resources/2019-national-facts.html 

About KidneyIntelX

KidneyIntelX, is a first-of-kind, bioprognostic(TM) platform that employs a proprietary artificial intelligence-enabled algorithm to combine diverse data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record, or EHR, systems, to generate a unique patient risk score. This patient risk score enables prediction of progressive kidney function decline in chronic kidney disease, or CKD, allowing physicians and healthcare systems to optimize the allocation of treatments and clinical resources to patients at highest risk.

About Renalytix

Renalytix (LSE: RENX) (NASDAQ: RNLX) is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company's lead product is KidneyIntelX, which has been granted Breakthrough Designation by the U.S. Food and Drug Administration and which is being designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com ). For more information, visit www.renalytix.com .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

IOERLMJTMTABBIB

(END) Dow Jones Newswires

July 19, 2021 10:02 ET (14:02 GMT)

1 Year Renalytix Chart

1 Year Renalytix Chart

1 Month Renalytix Chart

1 Month Renalytix Chart
ADVFN Advertorial
Your Recent History
LSE
RENX
Renalytix
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20210923 07:15:40